Lentinan from shiitake selectively attenuates AIM2 and non-canonical inflammasome activation while inducing pro-inflammatory cytokine production.
Huijeong AhnEunsaem JeonJin-Chul KimSeung Goo KangSung-Il YoonHyun-Jeong KoPyeung-Hyeun KimGeun-Shik LeePublished in: Scientific reports (2017)
Lentinan extracted from shiitake (Lentinula edodes) is a β-glucan that has been reported as an intravenous anti-tumor polysaccharide via enhancement of the host immune system. In this study, we determined the effect of lentinan on inflammasome activation, a multi-protein platform, in myeloid cells. Mouse bone marrow-derived macrophages were treated with lentinan with/without inflammasome triggers, and maturation of interleukin (IL)-1β, IL-18, or caspase-1 was measured as a readout of inflammasome activation. As a result, lentinan selectively inhibited absent in melanoma 2 (AIM2) inflammasome activation. In addition, lentinan up-regulated pro-inflammatory cytokines and induced expression of inflammasome-related genes through toll-like receptor 4 signaling. Furthermore, we assessed the effect of lentinan on mice treated with Listeria monocytogenes or lipopolysaccharide as an AIM2 or non-canonical inflammasome-mediated model. Lentinan attenuated IL-1β secretion resulting from Listeria-mediated AIM2 inflammasome activation and reduced endotoxin lethality via inhibition of non-canonical inflammasome activation. Thus, lentinan is suggested as an anti-AIM2 and anti-non-canonical inflammasome candidate despite its up-regulation of cytokine expression.
Keyphrases
- toll like receptor
- poor prognosis
- inflammatory response
- listeria monocytogenes
- type diabetes
- transcription factor
- adipose tissue
- metabolic syndrome
- acute myeloid leukemia
- dendritic cells
- low dose
- binding protein
- high dose
- diabetic rats
- lps induced
- single cell
- insulin resistance
- cell cycle arrest
- basal cell carcinoma
- protein protein
- water soluble